Search International and National Patent Collections

1. (WO2015116755) SOLID FORMS OF 2-(TERT-BUTYLAMINO)-4-((1R,3R,4R)-3-HYDROXY-4-METHYLCYCLOHEXYLAMINO)-PYRIMIDINE-5-CARBOXAMIDE, COMPOSITIONS THEREOF AND METHODS OF THEIR USE

Pub. No.:    WO/2015/116755    International Application No.:    PCT/US2015/013412
Publication Date: Fri Aug 07 01:59:59 CEST 2015 International Filing Date: Fri Jan 30 00:59:59 CET 2015
IPC: A61K 31/505
Applicants: SIGNAL PHARMACEUTICALS, LLC
Inventors: FERRETTI, Antonio Christian
MAN, Hon-Wah
MUSLEHIDDINOGLU, Jale
XU, Jean
YONG, Kelvin Hin-yeong
BEAUCHAMPS, Marie Georges
KOTHARE, Mohit Atul
ZOU, Nanfei
BOERSEN, Nathan Andrew
LI, Ying
HILGRAF, Robert
NAGY, Mark A.
ZOU, Daozhong
HUANG, Lianfeng
Title: SOLID FORMS OF 2-(TERT-BUTYLAMINO)-4-((1R,3R,4R)-3-HYDROXY-4-METHYLCYCLOHEXYLAMINO)-PYRIMIDINE-5-CARBOXAMIDE, COMPOSITIONS THEREOF AND METHODS OF THEIR USE
Abstract:
Provided herein are formulations, processes, solid forms and methods of use relating to 2-(tert-butylamino)-4-((1R,3R,4R)-3- hydroxy-4-methy1cydohexylamino)-pyrimidine-5-carboxamide (Compound I). In another aspect, provided herein are methods for preparing certain compounds, including Compound I as described herein, as well as intermediates useful in such methods. In certain aspects, the solid forms of Compound I are useful for inhibiting a kinase in a cell expressing said kinase, for example JNK1 or JNK2. In another aspect, the solid forms of Compound I are useful for treating or preventing one or more disorders selected from interstitial pulmonary fibrosis, systemic sclerosis, scleroderma, chronic allograft nephropathy, antibody mediated rejection, or lupus.